SureTrader Advertisement SureTrader
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 3
Posts 101
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Wall Street Not Rewarding Low-expectation Earnings Beats
Health-care, media, energy earnings start winding season down Earnings beats this season have been cheapened, with lower-than-usual...
Top Equities Stories Of The Day
FCC to Sell Maximum Amount in TV Airwave Auction
Fitbit Scores Against Jawbone in Patent Dispute
Valeant Default Fears 'Cured' -- WSJ
Exxon Swoons, but Investors Cheer -- WSJ
CBOE Reports Higher Earnings, Revenue Thanks to Trading Shift
Amazon Kindle Oasis Video Review: Up Close With the Luxury E-Reader
Drugmakers Place Big Bets on Cancer Medicines
Abbott to Acquire St. Jude -- WSJ
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 201066 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist